Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (TRI Pro)

2. november 2026 opdateret af: Janssen Research & Development, LLC

Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

230

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Buenos Aires, Argentina, C1199ABB
        • Rekruttering
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentina, C1426ANZ
        • Rekruttering
        • Instituto Alexander Fleming
      • Buenos Aires, Argentina, C1118
        • Rekruttering
        • Hospital Aleman
      • Córdoba, Argentina, X5016KEH
        • Rekruttering
        • Hospital Privado Centro Medico de Cordoba
      • Pilar, Argentina, 1629
        • Rekruttering
        • Hospital Universitario Austral
      • Bedford Park, Australien, 5042
        • Rekruttering
        • Flinders Medical Centre
      • Birtinya, Australien, 4575
        • Rekruttering
        • Sunshine Coast University Hospital
      • Concord, Australien, 2139
        • Rekruttering
        • Concord Repatriation General Hospital
      • Fitzroy, Australien, 3065
        • Rekruttering
        • St Vincents Hospital Melbourne
      • Wollongong, Australien, 2500
        • Rekruttering
        • Wollongong Hospital
    • Arizona
      • Goodyear, Arizona, Forenede Stater, 85338
        • Rekruttering
        • City of Hope Phoenix
    • California
      • Beverly Hills, California, Forenede Stater, 90211
        • Rekruttering
        • Beverly Hills Cancer Center (BHCC)
      • Irvine, California, Forenede Stater, 92618
        • Rekruttering
        • City of Hope Orange County Lennar Foundation Cancer Center
      • Palo Alto, California, Forenede Stater, 94304
        • Rekruttering
        • Stanford University Medical Center
    • Colorado
      • Denver, Colorado, Forenede Stater, 80218
        • Rekruttering
        • Colorado Blood Cancer Institute
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Washington University School Of Medicine
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43214
        • Rekruttering
        • Ohio Health Research Institute
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • Sarah Cannon Research Institute
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Rekruttering
        • University of Utah Huntsman Cancer Institute
      • Argenteuil, Frankrig, 95107
        • Rekruttering
        • Centre Hospitalier Victor Dupouy
      • Bayonne, Frankrig, 64100
        • Rekruttering
        • Centre Hospitalier de la Cote Basque
      • La Tronche, Frankrig, 38700
        • Rekruttering
        • CHU de Grenoble
      • Le Mans, Frankrig, 72100
        • Rekruttering
        • Centre de Cancerologie de la Sarthe
      • Nantes, Frankrig, 44000
        • Rekruttering
        • CHU Nantes - Hotel Dieu
      • Quimper, Frankrig, 29000
        • Rekruttering
        • Centre Hospitalier de Quimper Cornouaille
      • Alexandroupoli, Grækenland, 681 00
        • Rekruttering
        • Uni General Hospital of Alexandroupolis
      • Athens, Grækenland, 11528
        • Rekruttering
        • Alexandra General Hospital of Athens
      • Athens, Grækenland, 115 25
        • Rekruttering
        • 251 Air Force General Hospital
      • Piraeus, Grækenland, 18537
        • Rekruttering
        • Metaxa Cancer Center Hospital Of Piraeus
      • Rio, Grækenland, 265 04
        • Rekruttering
        • General University Hospital of Patras
      • Thessaloniki, Grækenland, 54642
        • Rekruttering
        • Hippokration Hospital
      • Thessaloniki, Grækenland, 546 39
        • Rekruttering
        • Theageneio Cancer Hospital
      • Ampang, Malaysia, 68000
        • Rekruttering
        • Hospital Ampang
      • George Town, Malaysia, 10450
        • Rekruttering
        • Hospital Pulau Pinang
      • Johor Bharu, Malaysia, 80100
        • Rekruttering
        • Hospital Sultanah Aminah
      • Kota Kinabalu, Malaysia, 88586
        • Rekruttering
        • Hospital Queen Elizabeth
      • Kuching, Malaysia, 93586
        • Rekruttering
        • Sarawak General Hospital
      • Braga, Portugal, 4710 243
        • Rekruttering
        • Uls Braga - Hosp. Braga
      • Lisbon, Portugal, 1099 023
        • Rekruttering
        • Ipo Lisboa
      • Lisbon, Portugal, 1998 018
        • Rekruttering
        • Hosp. Cuf Descobertas
      • Porto, Portugal, 4200 319
        • Rekruttering
        • Uls Sao Joao - Hosp. Sao Joao
      • Porto, Portugal, 4050 342
        • Rekruttering
        • Uls Santo Antonio - Hosp. Santo Antonio
      • Vila Nova de Gaia, Portugal, 4434 502
        • Rekruttering
        • Uls Gaia Espinho
      • Barcelona, Spanien, 08041
        • Rekruttering
        • Hosp. de La Santa Creu I Sant Pau
      • León, Spanien, 24071
        • Rekruttering
        • Hosp. de Leon
      • Madrid, Spanien, 28046
        • Rekruttering
        • Hosp. Univ. La Paz
      • Madrid, Spanien, 28055
        • Rekruttering
        • Hosp. Blua Sanitas Valdebebas
      • Málaga, Spanien, 29010
        • Rekruttering
        • Hosp Regional Univ de Malaga
      • Pamplona, Spanien, 31008
        • Rekruttering
        • Hosp. de Navarra
      • Valencia, Spanien, 46017
        • Rekruttering
        • Hosp. Univ. Dr. Peset
      • Falun, Sverige, 791 82
        • Rekruttering
        • Falu Lasarett Medicinkliniken Falun
      • Gothenburg, Sverige, 413 45
        • Rekruttering
        • Sahlgrenska Universitetssjukhuset
      • Lund, Sverige, 221 85
        • Rekruttering
        • Skanes universitetssjukhus
      • Stockholm, Sverige, 141 86
        • Rekruttering
        • Karolinska University Hospital Huddinge
      • Uppsala, Sverige, 752 37
        • Rekruttering
        • Akademiska Sjukhuset
      • Budapest, Ungarn, 1088
        • Rekruttering
        • Semmelweis Egyetem
      • Budapest, Ungarn, 1097
        • Rekruttering
        • Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely
      • Budapest, Ungarn, 1122
        • Rekruttering
        • Orszagos Onkologiai Intezet
      • Pécs, Ungarn, 7624
        • Rekruttering
        • Pecsi Tudomanyegyetem Klinikai Kozpont
      • Szeged, Ungarn, 6725
        • Rekruttering
        • Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria:

  • Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. Measurable disease at screening as assessed by local laboratory as defined in the protocol
  • Received at least 1 prior lines of antimyeloma therapy
  • Relapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
  • Have an eastern cooperative oncology group (ECOG) performance status (PS) score of 0 to 2 at screening and immediately before the start of study treatment administration. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy
  • Have clinical laboratory values meeting the criteria specified in the protocol

Exclusion criteria:

  • Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or investigational agent
  • Major surgery, (for example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
  • Suspected or known allergies, hypersensitivity, or intolerance to ramantamig and tocilizumab or their excipients
  • Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM
  • Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm A: Tocilizumab + Ramantamig

Participants will receive tocilizumab along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until progressive disease (PD) or intolerable toxicity (whichever is earlier).

Ramantamig will be administered as subcutaneous (SC) injection.

Andre navne:
  • JNJ-79635322

Tocilizumab will be administered as intravenous (IV) injection.

Placebo komparator: Arm B: Placebo + Ramantamig

Participants will receive placebo (saline) along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until PD or intolerable toxicity (whichever is earlier).

Ramantamig will be administered as subcutaneous (SC) injection.

Andre navne:
  • JNJ-79635322

Placebo (saline) will be administered as IV injection.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)
Tidsramme: By the end of Day 28 from first ramantamig dose

Percentage of participants alive and free of treatment-emergent ASTCT Grade >=2 CRS without the use of intervening treatment for CRS of any grade by the end of day 28 from first ramantamig dose will be reported.

By the end of Day 28 from first ramantamig dose

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig Dose
Tidsramme: By the end of Day 28 from first ramantamig dose

Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the end of day 28 from first ramantamig dose, respectively, will be reported.

By the end of Day 28 from first ramantamig dose
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig Treatment
Tidsramme: Up to 38 months

Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 during ramantamig treatment will be reported.

Up to 38 months
Percentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS Event
Tidsramme: Up to 38 months

Percentage of participants with re-occurrence of CRS with ASTCT Grade >=2 after the initial occurrence of treatment-emergent Grade >=2 CRS event will be reported.

Up to 38 months
Percentage of Participants with Re-occurrence of CRS for All Grades
Tidsramme: Up to 38 months

Percentage of participants with re-occurrence of CRS for all Grades will be reported.

Up to 38 months
Overall Response
Tidsramme: Up to 38 months

Overall response is defined as the percentage of participants who achieve partial response (PR) or better prior to progressive disease (PD) or subsequent antimyeloma therapy, in accordance with the international myeloma working group (IMWG) criteria.

Up to 38 months
Complete Response (CR) or Better
Tidsramme: Up to 38 months

CR or better rate is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria.

Up to 38 months
Very Good Partial Response (VGPR) or Better
Tidsramme: Up to Month 38

VGPR or better rate is defined as the percentage of participants achieving VGPR, CR or sCR prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria.

Up to Month 38
Duration of Response (DoR)
Tidsramme: Up to 38 months

DoR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of PD according to the IMWG response criteria or death due to any cause, whichever occurs first.

Up to 38 months
Time to Response (TTR)
Tidsramme: Up to 38 months

TTR is defined as the time from the date of randomization to the date of first documentation of a confirmed response (PR or better) for participants who have PR or better as their best response.

Up to 38 months
Progression-Free Survival (PFS)
Tidsramme: Up to Month 38

PFS is defined as the duration from the date of randomization to either PD or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria.

Up to Month 38
Time to Subsequent Antimyeloma Therapy
Tidsramme: Up to Month 38

Time to subsequent antimyeloma therapy is defined as the time from randomization to the start of subsequent antimyeloma treatment. Death due to progressive disease without the start of any subsequent antimyeloma therapy will be considered as an event.

Up to Month 38
Percentage of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
Tidsramme: Up to 38 months

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent antimyeloma therapy, whichever is earlier, or any follow-up AE (linked to an existing TEAE) with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent therapy, or any AE that is considered treatment-related regardless of the start date of the event, is considered to be treatment-emergent. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event.

Up to 38 months
Percentage of Participants with Abnormalities in Laboratory Parameters
Tidsramme: Up to 38 months

Percentage of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported.

Up to 38 months
Percentage of Participants with Incidence of Adverse Events of Clinical Interests
Tidsramme: Up to 38 Months

Percentage of participants with incidence of adverse events of clinical interests such as cytopenia will be reported.

Up to 38 Months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. juni 2026

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

30. juli 2030

Datoer for studieregistrering

Først indsendt

11. maj 2026

Først indsendt, der opfyldte QC-kriterier

11. maj 2026

Først opslået (Faktiske)

15. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 79635322MMY2002
  • 2025-524793-42 (EudraCT nummer)
  • 2025 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .